AlphaCentric Advisors’s Gossamer Bio GOSS Stock Holding History

AlphaCentric Advisors’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,000	Closed	-$145K	–	214
2020 Q4	$145K	Buy	+15,000	New	+$148K	0.06%	90

Other funds holding GOSS

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

AlphaCentric Advisors's GOSS Position: Q1 2021 in Review

AlphaCentric Advisors sold out of Gossamer Bio (GOSS) in Q1 2021, closing a stake of 15,000 shares — an estimated $145K sold.

AlphaCentric Advisors first reported a position in GOSS in Q4 2020 and held it in 1 quarter. The position peaked at $145K in Q4 2020. 123 funds tracked by Wall St. Rank hold GOSS as of Q1 2021.

AlphaCentric Advisors reported no remaining Gossamer Bio position as of Q1 2021 after selling out during the quarter.
AlphaCentric Advisors sold 15,000 Gossamer Bio shares in Q1 2021, an estimated $145K.
AlphaCentric Advisors first reported a position in Gossamer Bio in Q4 2020 and held it in 1 quarter.
AlphaCentric Advisors's Gossamer Bio position peaked at $145K in Q4 2020.
123 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2021.

Based on AlphaCentric Advisors's 13F filing for Q1 2021, filed 9 Mar 2022.